Citation Impact
Citing Papers
Long-term therapy of chronic delta hepatitis with peginterferon alfa
2014
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Cancer statistics, 2022
2022 Standout
Cancer statistics, 2023
2023 Standout
Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease
2020
A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
2016
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Specific Effects of Biliopancreatic Diversion on the Major Components of Metabolic Syndrome
2005
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
2017
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
2022
Limitations of non-invasive tests for assessment of liver fibrosis
2020
Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD
2015
Relationship between gut microbiota and circulating metabolites in population-based cohorts
2019
Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: A cost-effectiveness analysis
2011
Hepatocellular carcinoma
2018 Standout
AMPK: guardian of metabolism and mitochondrial homeostasis
2017 Standout
NAFLD: Reporting Histologic Findings in Clinical Practice
2020
Autoimmune hepatitis: a review
2012
Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells
2011
Liver cirrhosis
2014
Pro-resolving lipid mediators are leads for resolution physiology
2014 StandoutNature
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
2019 Standout
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
2012 StandoutNature
Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases
2013
The Role of Cholesterol in the Pathogenesis of NASH
2015
Intensive Care Unit Management of Patients with Liver Failure
2014
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
2022
Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?
2016
A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy
2012
Acute-on chronic liver failure
2012
Diagnosis and Management of Autoimmune Hepatitis
2010
Progression to Cirrhosis Leads to Improvement in Atherogenic Milieu
2020
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
2014 Standout
Gut Microbes and the Brain: Paradigm Shift in Neuroscience
2014
Mechanisms and disease consequences of nonalcoholic fatty liver disease
2021
Coordinated Transcription of Key Pathways in the Mouse by the Circadian Clock
2002 Standout
Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect
2016 Standout
Pharmacotherapy for NASH: Current and emerging
2017
Relationship between resolution of non‐alcoholic steatohepatitis and changes in lipoprotein sub‐fractions: a post‐hoc analysis of the PIVENS trial
2019
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
2020
Burden of Cirrhosis on Older Americans and Their Families
2011
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
2020
Metazoan MicroRNAs
2018 Standout
Biodistribution and function of extracellular miRNA-155 in mice
2015 StandoutNobel
Acute kidney injury
2019 Standout
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
2013
The role of scavenger receptor class B type I (SR-BI) in lipid trafficking
2003
Non-alcoholic fatty liver disease
2021 Standout
The role of the gut microbiota in NAFLD
2016
Antiviral strategies in hepatitis C virus infection
2012
In-Hospital Mortality and Economic Burden Associated With Hepatic Encephalopathy in the United States From 2005 to 2009
2012
The ins and outs of hepatitis C virus entry and assembly
2013 StandoutNobel
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
2012 Standout
Global patterns and trends in colorectal cancer incidence in young adults
2019
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement
2011
Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
2012
Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease
2020
Introduction to the revised American Association for the Study of Liver Diseases position paper on acute liver failure 2011
2011
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
2009
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
2019
Hepatitis C Virus-Specific Directly Acting Antiviral Drugs
2013
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
2017
Relation of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease to Left Ventricular Diastolic Function and Exercise Tolerance
2018
Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis
2013 Standout
Hepatitis C Virus Entry
2007 StandoutNobel
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Antibiotics for the treatment of hepatic encephalopathy
2013
Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications
2016
Clinical states of cirrhosis and competing risks
2017
Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease
2020
Inflammation, metaflammation and immunometabolic disorders
2017 StandoutNature
Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
2014
What Are the Promising New Therapies in the Field of Chronic Hepatitis C After the First-Generation Direct-Acting Antivirals?
2012
Minimal Hepatic Encephalopathy and Driving: Is the Genie Out of the Bottle?
2011
Fatty liver is an independent predictor of early carotid atherosclerosis
2016
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis
2010
Hepatobiliary transport
2000
A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care?
2013
Review article: specifically targeted anti‐viral therapy for hepatitis C – a new era in therapy
2010
Treatment of Chronic Hepatitis C: Current and Future
2013
Gut microbiota in human metabolic health and disease
2020 Standout
The role of inflammation in depression: from evolutionary imperative to modern treatment target
2015 Standout
Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis
2017
Update on primary sclerosing cholangitis
2013
Regulation of bile acid synthesis
1998
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis
2020 StandoutNobel
Hepatocellular Carcinoma
2019 Standout
The Role of the High-Density Lipoprotein Receptor SR-BI in the Lipid Metabolism of Endocrine and Other Tissues
2003
Palliative care for patients with end‐stage liver disease: An overview
2015
Treatment of nonalcoholic fatty liver disease: role of AMPK
2016
Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
2000 Standout
The Enzymes, Regulation, and Genetics of Bile Acid Synthesis
2003 Standout
Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
2021
Ultrastructural analysis of hepatitis C virus particles
2013 StandoutNobel
Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
2015
Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells
2012 StandoutNobel
The role of the gut microbiome in chronic liver disease: the clinical evidence revised
2019
High-Avidity Monoclonal Antibodies against the Human Scavenger Class B Type I Receptor Efficiently Block Hepatitis C Virus Infection in the Presence of High-Density Lipoprotein
2007 StandoutNobel
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
De Novo Lipogenesis Products and Endogenous Lipokines
2016
Introduction to the human gut microbiota
2017 Standout
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities
2021
Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity
2016 Standout
Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review
2017
Identification of AP80978, a Novel Small-Molecule Inhibitor of Hepatitis C Virus Replication That Targets NS4B
2014 StandoutNobel
MicroRNA-223 coordinates cholesterol homeostasis
2014
Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases
2021
Linkage of gut microbiome with cognition in hepatic encephalopathy
2011
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
2020
Medication noncompliance in schizophrenia: codification and update.
1986
Coronary artery disease in decompensated patients undergoing liver transplantation evaluation
2018
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Development of novel treatments for hepatitis C
2009
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents
2014 StandoutNobel
A Lipidomic Readout of Disease Progression in A Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease.
2015
Cholesterol Synthesis Inhibition Elicits an Integrated Molecular Response in Human Livers Including Decreased ACAT2
2008 StandoutNobel
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
2017
Cutting Edge: Chronic Inflammatory Liver Disease in Mice Expressing a CD28-Specific Ligand
2012 StandoutNobel
Hepatitis C Virus Genotype 5a Subgenomic Replicons for Evaluation of Direct-Acting Antiviral Agents
2014 StandoutNobel
Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation
2018
A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition
2017
Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop
2014
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants
2009 StandoutNobel
Works of Michael Fuchs being referenced
Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial
2017
Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
2013
Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: Implications for the gut-liver-brain axis
2014
The plasma lipidomic signature of nonalcoholic steatohepatitis†‡
2009
Covert Hepatic Encephalopathy Is Independently Associated With Poor Survival and Increased Risk of Hospitalization
2014
Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis
2020
The Multi-Dimensional Burden of Cirrhosis and Hepatic Encephalopathy on Patients and Caregivers
2011
Association Between High-Normal Levels of Alanine Aminotransferase and Risk Factors for Atherogenesis
2013
Driving Simulation Can Improve Insight into Impaired Driving Skills in Cirrhosis
2011
Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile
2014
Biliary Cholesterol Hypersecretion in Gallstone–Susceptible Mice Is Associated With Hepatic Up–Regulation of the High–Density Lipoprotein Receptor Srbi
2001
Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance)
2014
Modulation of the fecal bile acid profile by gut microbiota in cirrhosis
2013
Lipotoxicity in NASH
2011
The Stroop Smartphone Application Is A Short And Valid Method To Screen for Minimal Hepatic Encephalopathy
2013
Rifaximin Improves Driving Simulator Performance in a Randomized Trial of Patients With Minimal Hepatic Encephalopathy
2010
Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease
2012
Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography
2011
A Single Center Review of the Use of Mycophenolate Mofetil in the Treatment of Autoimmune Hepatitis
2008
[586] SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BILB1941, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C
2007
Depot fluphenazine in the treatment of psychosis in a community mental health clinic.
1970
Evidence for an ATP-independent long-chain phosphatidylcholine translocator in hepatocyte membranes
1997
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
2019
III. Regulation of bile acid synthesis: past progress and future challenges
2003
Colonic inflammation and secondary bile acids in alcoholic cirrhosis
2014
Deoxycholate and cholate modulate the source of cholesterol substrate for bile acid synthesis in the rat
1995
Herpes simplex virus colitis in a patient with Crohn's disease and hepatitis B and d cirrhosis.
2010
Herpes Simplex Virus Colitis in a Patient with Crohnʼs Disease and Hepatitis B and D Cirrhosis
2008
Non-Alcoholic Fatty Liver Disease: The Bile Acid-Activated Farnesoid X Receptor as an Emerging Treatment Target
2011
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment
2009